SAREPTA THERAPEUTICS, INC.

Lobbying for SAREPTA THERAPEUTICS, INC.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · Senate · $430,000.00 expenses · posted Oct 15, 2025

Lobbying activity 4

Health Issues

Issues related to patient access to treatments Issues related to rare diseases such as Duchenne Muscular Dystrophy Issues related to newborn screening for rare diseases

Pharmacy

Issues related to the Inflation Reduction Act's prescription drug provisions

Science/Technology

Issues related to scientific innovation in healthcare such as gene therapies Issues related to artificial intelligence and data governance

Taxation/Internal Revenue Code

Tax issues related to research and development

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.